Effects of lisdexamfetamine in a rat model of binge-eating

Journal of Psychopharmacology

Volumn 29, Issue 12, 2015, Pages 1290-1307

  Vickers, Steven P ^a   Hackett, David ^b   Murray, Fraser ^b   Hutson, Peter H ^c   Heal, David J ^a  

^a RenaSci Ltd   (United Kingdom)

^b Shire Pharmaceuticals   (United Kingdom)

^c SHIRE   (United States)

Author keywords

binge eating; binge eating disorder; d amphetamine; Lisdexamfetamine; rats

Indexed keywords

1 (2 METHYL 6 BENZOXAZOLYL) 3 (1,5 NAPHTHYRIDIN 4 YL)UREA; 2 (2 METHOXY 1,4 BENZODIOXAN 2 YL) 2 IMIDAZOLINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ALPHA 1 ADRENERGIC RECEPTOR; BACLOFEN; DEXAMPHETAMINE; DOPAMINE 1 RECEPTOR; LISDEXAMFETAMINE; NALMEFENE; OLANZAPINE; PRAZOSIN; RACLOPRIDE; ROLIPRAM; SIBUTRAMINE; 2-METHOXYIDAZOXAN; BENZAZEPINE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; IDAZOXAN; NALTREXONE; PRODRUG;

ADRENERGIC STIMULATION; ADULT; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINGE EATING DISORDER; BODY WEIGHT; CACAO; CALORIC INTAKE; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DRUG MECHANISM; DRUG RESPONSE; FEEDING BEHAVIOR; FEMALE; FLUID INTAKE; FOOD INTAKE; NONHUMAN; PRIORITY JOURNAL; RAT; ANALOGS AND DERIVATIVES; ANIMAL; BULIMIA; DISEASE MODEL; DRUG EFFECTS; EATING; WISTAR RAT;

ANIMALS; BACLOFEN; BEHAVIOR, ANIMAL; BENZAZEPINES; BENZODIAZEPINES; BODY WEIGHT; BULIMIA; DISEASE MODELS, ANIMAL; EATING; FEEDING BEHAVIOR; FEMALE; IDAZOXAN; LISDEXAMFETAMINE DIMESYLATE; NALTREXONE; PRAZOSIN; PRODRUGS; RACLOPRIDE; RATS; RATS, WISTAR; ROLIPRAM;

EID: 84948686084     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881115615107     Document Type: Article

References (73)

1. Allison KC, Wadden TA, Sarwer DB, et al. (2006) Night eating syndrome and binge eating disorder among persons seeking bariatric surgery: prevalence and related features. Obesity 14: 77S-82S.
2. American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA: American Psychiatric Association (2013). Available at: dsm.psychiatryonline.org (. accessed 1 June 2013).
3. Apfelbaum M, Vague P, Ziegler O, et al. (1999) Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 106: 179-184.
4. Appolinario JC, Bacaltchuk J, Sichieri R, et al. (2003) A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder. Arch Gen Psychiatry 60: 1109-1116.
5. Arnold LM, McElroy SL, Hudson JI, et al. (2002) A placebo-controlled, randomized trial of fluoxetine in the treatment of binge-eating disorder. J Clin Psychiatry 63: 1028-1033.
6. Berner LA, Bocarsly ME, Hoebel BG, et al. (2009) Baclofen suppresses binge eating of pure fat but not a sugar-rich or sweet-fat diet. Behav Pharmacol 20: 631-634.
7. Bisaga A, Danysz W, Foltin RW, (2008) Antagonism of glutamatergic NMDA and mGluR5 receptors decreases consumption of food in baboon model of binge-eating disorder. Eur Neuropsychopharmacol 18: 794-802.
8. Citrome L, (2015) Lisdexamfetamine for binge eating disorder in adults: a systematic review of the efficacy and safety profile for this newly approved indication-what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 69: 410-421.
9. ClinicalTrials.gov (2014) Available at: http://clinicaltrials.gov/ct2/show/NCT01921582?term=binge+eating&rank=8.
10. Corwin RL, (2004) Binge-type eating induced by limited access in rats does not require energy restriction on the previous day. Appetite 42: 139-142.
11. Corwin RL, Avena NM, Boggiano MM, (2011) Feeding and reward: perspectives from three rat models of binge eating. Physiol Behav 104: 87-97.
12. Corwin RL, Boan J, Peters KF, et al. (2012) Baclofen reduces binge eating in a double-blind, placebo-controlled, crossover study. Behav Pharmacol 23: 616-625.
13. Corwin RL, Wojnicki FH, Fisher JO, et al. (1998) Limited access to a dietary fat option affects ingestive behavior but not body composition in male rats. Physiol Behav 65: 545-553.
14. Cottone P, Sabino V, Steardo L, et al. (2008) Opioid-dependent anticipatory negative contrast and binge-like eating in rats with limited access to highly preferred food. Neuropsychopharmacol 33: 524-535.
15. Dahl JK, Eriksen L, Vedul-Kjelsås E, et al. (2010) Prevalence of all relevant eating disorders in patients waiting for bariatric surgery: a comparison between patients with and without eating disorders. Eat Weight Disord 15: e247-255.
16. Davis TG, Peterson JJ, Kou J-P, et al. (2009) The identification of a novel phosphodiesterase-4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}- N -(tetrahydro-2 H -pyran-4-yl)-1 H -pyrazolo[3,4- b ]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity. J Pharmacol Exp Ther 330: 922-931.
17. de Jong JW, Meijboom KE, Vanderschuren LJMJ, et al. (2013) Low control over palatable food intake in rats is associated with habitual behavior and relapse vulnerability: individual differences. PLoS ONE 8: e74645.
18. de Zwaan M, Mitchell JE, Seim HC, et al. (1994) Eating related and general psychopathology in obese females with binge eating disorder. Int J Eat Disord 15: 43-52.
19. Dickinson K, North TJ, Anthony DM, et al. (1998) Evaluation of a simplified cafeteria model for the induction of insulin resistant obesity in rats. Int J Obes 22: S19.
20. Dimitriou SG, Rice HB, Corwin RL, (2000) Effects of limited access to a fat option on food intake and body composition in female rats. Int J Eat Disord 28: 436-445.
21. Dingemans AE, Bruna MJ, van Furth EF, (2002) Binge eating disorder: a review. Int J Obes 26: 299-307.
22. Dyke HJ, Montana JG, (2002) Update on the therapeutic potential of PDE4 inhibitors. Exp Opin Investig Drugs 11: 1-13.
23. FDA (2015) FDA expands uses of Vyvanse to treat binge-eating disorder. Press release, available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm432543.htm
24. Fell MJ, Neill JC, Anjum N, et al. (2008) Investigation into the influence of a high fat diet on antipsychotic-induced weight gain in female rats. Psychopharmacology 22: 182-186.
25. Galanti K, Gluck ME, Geliebter A, (2007) Test meal intake in obese binge eaters in relation to impulsivity and compulsivity. Int J Eat Disord 40: 727-732.
26. Giuliano C, Robbins TW, Nathan PJ, et al. (2012) Inhibition of opioid transmission at the μ-opioid receptor prevents both food seeking and binge-like eating. Neuropsychopharmacology 37: 2643-2652.
27. Goldschmidt AB, Le Grange D, Powers P, et al. (2011) Eating disorder symptomatology in normal-weight vs obese individuals with binge-eating disorder. Obesity 19: 1515-1518.
28. Halford JC, Wanninayake SC, Blundell JE, (1998) Behavioral satiety sequence (BSS) for the diagnosis of drug action on food intake. Pharmacol Biochem Behav 61: 159-168.
29. Heal DJ, Gosden J, Jackson HC, et al. (2012) Metabolic consequences of antipsychotic therapy: preclinical and clinical perspectives on diabetes, diabetic ketoacidosis, and obesity. Handb Exp Pharmacol 212: 135-164.
30. Heal DJ, Vickers SP, Hackett D, et al. (2013) Metabolic effects of lisdexamfetamine in a rat model of human obesity with insulin resistance. Eur Neuropsychoparmacol 23: S207.
31. Hebenstreit GF, Fellerer K, Fichte K, et al. (1989) Rolipram in major depressive disorder: results of a double-blind comparative study with imipramine. Pharmacopsychiatry 22: 156-160.
32. Hoek HW, van Hoeken D, (2003). Review of the prevalence and incidence of eating disorders. Int J Eat Disord 34: 383-96.
33. Hu Y, Young AJ, Ehli EA, et al. (2014). Metformin and berberine prevent olanzapine-induced weight gain in rats. PLoS One 9 (3): e93310.
34. Hudson JI, Hiripi E, Pope HG Jr, et al. (2007) The prevalence and correlates of eating disorders in the National Comorbidity Survey. Replication Biol Psychiatry 61: 348-358.
35. Hutson PH, Pennick M, Secker R, (2014) Preclinical pharmacokinetics, pharmacology and toxicology of lisdexamfetamine: a novel d-amphetamine pro-drug. Neuropharmacol 87C: 41-50.
36. Ignar DM, Goetz AS, Noble KN, et al. (2011) Regulation of ingestive behaviors in the rat by GSK1521498, a novel μ-opioid receptor-selective inverse agonist. J Pharmacol Exp Ther 339: 24-34.
37. Ingman K, Hagelberg N, Aalto S, et al. (2005) Prolonged central μ-opioid receptor occupancy after single and repeated nalmefene dosing. Neuropsychopharmacology 30, 2245-2253.
38. Jääskeläinen A, Nevaapera N, Remes J, et al. (2014) Stress-related eating, obesity and associated behavioral traits in adolescents: a prospective population-based cohort study. BMC Pub Hlth 14: 321.
39. Jackson HC, Bearham MC, Hutchins LJ, et al. (1997) Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat. Brit J Pharmacol 121: 1613-1618.
40. James WP, Astrup A, Finer N, et al. (2000) Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 356: 2119-2125.
41. Lynch WC, Heil DP, Wagner E, et al. (2008) Body dissatisfaction mediates the association between body mass index and risky weight control behaviors among white and native American adolescent girls. Appetite 51: 210-213.
42. Masheb RM, Grilo CM, Brondolo E, (1999) Shame and its psychopathologic correlates in two women's health problems: binge eating disorder and vulvodynia. Eat Weight Disord 4: 187-193.
43. McElroy SL, Arnold LM, Shapira NA, et al. (2003a) Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry 160: 255-261.
44. McElroy SL, Guerdjikova AI, Blom TJ, et al. (2013) A placebo-controlled pilot study of the novel opioid receptor antagonist ALKS-33 in binge eating disorder. Int J Eat Disord 46: 239-245.
45. McElroy SL, Guerdjikova A, Kotwal R, et al. (2007) Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial. J Clin Psychiatry 68: 390-398.
46. McElroy SL, Hudson JI, Malhotra S, et al. (2003b) Citalopram in the treatment of binge-eating disorder: a placebo-controlled trial. J Clin Psychiatry 64: 807-813.
47. McElroy SL, Hudson J, Celeste Ferreira-Cornwell M, et al. (2015a) Lisdexamfetamine dimesylate for adults with moderate to severe binge eating disorder: results of two pivotal Phase 3 randomized controlled trials. Neuropsychopharmacology JAMA 72: 235-246.
48. McElroy SL, Hudson JI, Mitchell JE, et al. (2015b) Efficacy and safety of lisdexamfetamine dimesylate for treatment of adults with moderate to severe binge eating disorder: a randomized, double-blind, placebo-controlled trial. JAMA Psychiatry 72: 235-246.
49. McElroy SL, Kotwal R, Guerdjikova AI, et al. (2006) Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. J Clin Psychiatry 67: 1897-1906.
50. Milano W, Petrella C, Casella A, et al. (2005) Use of sibutramine, an inhibitor of the reuptake of serotonin and noradrenaline, in the treatment of binge-eating disorder: a placebo-controlled study. Adv Ther 22: 25-31.
51. Nathan PJ, Bullmore ET, (2009) From taste hedonics to motivational drive: central μ-opioid receptors and binge-eating behaviour. Int J Neuropsychopharmacol 12: 995-1008.
52. Newcomer JW, (2005) Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19: 1-93.
53. Pennick M, (2010) Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d- amphetamine. Neuropsychiatry Dis Treat 24: 317-327
54. Piccoli L, Micioni Di, Bonaventura MV, Cifani C, et al. M (2012) Role of orexin-1 receptor mechanisms on compulsive food consumption in a model of binge eating in female rats. Neuropsychopharmacology 37: 1999-2011.
55. Qian J, Hu Q, Wan Y, et al. (2013). Prevalence of eating disorders in the general population: a systematic review. Shanghai Arch Psychiatry 25: 212-23.
56. Reslan S, Saules KK, (2013) Assessing the prevalence of and factors associated with overweight, obesity, and binge eating as a function of ethnicity. Eat Weight Disord 18: 209-219.
57. Rigaud D, Jiang T, Pennacchio H, et al. (2014) Triggers of bulimia and compulsion attacks: validation of the "start" questionnaire. Encephale 40: 323-329.
58. Robbins TW, Gillan CM, Smith DG, et al. (2012) Neurocognitive endophenotypes of impulsivity and compulsivity: towards dimensional psychiatry. Trends Cogn Sci 16: 81-91.
59. Rowley HL, Kulkarni RS, Gosden J, et al. (2012) Lisdexamfetamine and immediate release d- amphetamine-differences in pharmacokinetic/pharmacodynamic relationships revealed by striatal microdialysis in freely-moving rats with simultaneous determination of plasma drug concentrations and locomotor activity. Neuropharmacol 63: 1064-1074.
60. Rowley HL, Kulkarni RS, Gosden J, et al. (2014) Differences in the neurochemical and behavioural profiles of lisdexamfetamine, methylphenidate and modafinil revealed by simultaneous dual-probe microdialysis and locomotor activity measurements in freely-moving rats. J Psychopharmacol 28: 254-269.
61. Schag K, Schonleber J, Teufel M, et al. (2013): Food-related impulsivity in obesity and binge eating disorder-a systematic review. Obes Rev 14: 477-495.
62. Sharman J, Pennick M, (2014) Lisdexamfetamine prodrug activation by peptidase-mediated hydrolysis in the cytosol of red blood cells. Neuropsychiatric Dis Treat 10: 2275-2280.
63. Sonneville KR, Calzo JP, Horton NJ, et al. (2012) Body satisfaction, weight gain and binge eating among overweight adolescent girls. Int J Obes 36: 944-949.
64. Suplicy H, Boguszewski CL, Dos Santos CM, et al. (2014) A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. Int J Obes 38: 1097-1103.
65. Vannucci A, Theim KR, Kass AE, et al. (2013) What constitutes clinically significant binge eating? Association between binge features and clinical validators in college-age women. Int J Eat Disord 46: 226-232.
66. 2C receptors. Neuropharmacology 41: 200-209.
67. Voon V, Derbyshire K, Ruck C, et al. (2015) Disorders of compulsivity: a common bias towards learning habits. Mol Psychiatry 20: 345-352.
68. Wilfley DE, Crow SJ, Hudson JI, et al.; Sibutramine Binge-eating Disorder Research Group (2008) Efficacy of sibutramine for the treatment of binge-eating disorder: a randomized multicenter placebo-controlled double-blind study. Am J Psychiatry 165: 51-58.
69. Williams DA, (1971) A test for differences between treatment means when several dose levels are compared with a zero dose control. Biometrics 27: 103-117.
70. Williams D.A,. (1972) The comparison of several dose levels with a zero dose control. Biometrics 28: 519-531.
71. Wonderlich SA, Gordon KH, Mitchell JE, et al. (2009) The validity and clinical utility of binge-eating disorder. Int J Eat Disord 42: 687-705.
72. Wong KJ, Wojnicki FHW, Corwin RLW, (2009) Baclofen, raclopride, and naltrexone differentially affect intake of fat/sucrose mixtures under limited access conditions. Pharmacol Biochem Behav 92: 528-536.
73. Yanovski S, (2003) Sugar and fat: cravings and aversions. J Nutr 133, 835S-837S.